Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study to Investigate the Safety and Feasibility of AntiRetroviral Therapy for Alzheimer's Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Aged 50-99 years~2. Clinical diagnosis of early Alzheimer's disease (Clinical Dementia Rating (CDR) = 0.5, Mini-Mental State Exam (MMSE) = 24-30)~3. If using drugs to treat symptoms related to Alzheimer's disease, doses must be stable for at least eight weeks prior to screening visit 1~4. Labs: Adequate blood cell counts (white blood cells: 4,000-111,000 cells per microliter (cells/mcL); absolute neutrophil count: 1,800-8,700 cells/mcL; platelets: 120-500 K/µL; hemoglobin 12.0-17.5 grams/dL); LFT's within 2x normal value; creatinine clearance test (CrCl) ≥ 50 mL/min; cholesterol (≤260 mg/dl), triglycerides≤ 400 mg/dl), and glucose control (HbA1c ≤ 8%). Prothrombin time/partial thromboplastin time/international normalized ratio (PT/PTT/INR) within normal limits~5. Body mass index (BMI) within range of 19 - 35 kg/m2~6. Must have a reliable informant or caregiver~7. Participants must have no plans to travel that interfere with study visits~Exclusion Criteria:~1. Any medical or neurologic condition (other than Alzheimer's Disease) that might be a contributing cause of the subject's cognitive impairment~2. Clinically significant unstable psychiatric illness in the past six months~3. Significant hearing, vision, or motor deficits that interfere with participation~4. Alcohol or drug abuse/dependence in the past six months~5. Stroke, transient ischemic attack, or unexplained loss of consciousness in the past six months~6. Unstable angina, myocardial infarction, advanced chronic heart failure, or clinically significant conduction abnormalities within the past six months~7. Relevant brain hemorrhage, bleeding disorder and cerebrovascular abnormalities~8. Diagnosis of HIV infection or AIDS (CD4 count \< 200), HIV/Hepatitis B Virus (HBV) co-infection, HBV or human T-cell leukemia virus infection~9. History of impaired renal or liver function~10. Current use of memantine or sorbitol-containing products~11. Individuals with HIV, HBV, or who have current/previous use of Nucleoside Reverse Transcriptase Inhibitors (NRTIs) or non-NRTIs.~12. Poorly controlled blood pressure (BP) (systolic BP \> 160, diastolic BP \> 90 mmHg)~13. Uncontrolled diabetes (HbA1c \> 8%, or the current use of insulin)~14. Significant systematic illness or infection in the past 30 days~15. Pregnant women

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Open-Label 3TC (Type: EXPERIMENTAL): 12 subjects will receive 3TC, 300-mg, daily for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).